Clinical Study

Merkel Cell Carcinoma: A Retrospective Study on 48 Cases and Review of Literature

Fernando Cirillo, Marco Vismarra, Ines Cafaro, and Mario Martinotti

1 Department of General Surgery, General Surgery Unit, Rare Hormonal Tumors Group, Surgery of Rare Hormonal Tumors, Azienda Ospedaliera Istituti Ospitalieri, Viale Concordia 1, 26100 Cremona, Italy
2 Radiotherapy Unit and Nuclear Medicine, Azienda Ospedaliera Istituti Ospitalieri, Viale Concordia, 1, 26100 Cremona, Italy

Correspondence should be addressed to Fernando Cirillo, f.cirillo@neuroendocrini.it

Received 19 March 2012; Revised 28 June 2012; Accepted 13 August 2012

Copyright © 2012 Fernando Cirillo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of the skin. Forty-eight patients with MCC were observed at the Rare Hormonal Tumors Group of Cremona Hospital, 15 of these with unknown primary site. Due to rarity of Merkel cell carcinoma, clinical experience is generally limited. Data from our series confirm the current recommendations. Wide surgical excision must be associated with radiotherapy also in early stages in order to avoid local relapse and the rapid progression of disease. In advanced stages chemotherapy is the standard despite the short duration of responses and poor quality of life. The data of our series, characterized by a high demand for second opinion, offer some insight about the real rarity of the tumor, the difficulty of managing of disease in our country secondary to a wrong cultural approach to the problem, the indiscriminate use of molecules unnecessary and often expensive, the lack of protocols, and the presence of guidelines often ignored. This results in very poor survival associated with a very low quality of life, requiring to find the right direction towards a correct management of disease.

1. Introduction

Merkel cell carcinoma (MCC) is a rare and aggressive tumor of the skin described for the first time by Toker, in 1972 [1] as a trabecular carcinoma of the skin, suggesting the origin from the cells of the sweat glands, with a later ultrastructural demonstration of neurosecretory granules that places the neoplasm from the Merkel cells [2]. At the beginning of the 1980s, other authors contributed to the discussion on the suitability of the term suggested by Toker, introducing a great variety of alternative names ("primitive small cell carcinoma of the skin," "malignant Merkel cell carcinoma," "Murky cell carcinoma," "Merkeloma") [3–8]. Finally, histochemical and histogenetic studies coined the term "neuroendocrine carcinoma of the skin" for this neoplasm placing it, therefore, in the large family of APUDomas [9–16], even if the true origin of the tumor from Merkel cell has not been proved definitively. It was also postulated the derivation of Merkel cell from the neural crest, the separation from the cells of Schwann, and the following migration from mesenchyma to epidermis as prolongation of the sensitive nerves of the derma [14]. MCC is currently considered deriving from an epithelial totipotent cell able to differentiate it both in neuroendocrine way, and as cheratinocita [15]. The presence of transitional cells similar both to the cheratinocytis and Merkel cells gives support to this theory.

The definite function of Merkel cell is not clear yet. The nearby contact with sensitive fibers would make to suppose a role of Merkel cell in the process of transition for some nervous stimulus; an influence is also possible on the secrection of neuropeptides as paracrine regulators on the near structures of the epidermis and adnexa [15]. Our observation of a consistent number of cases of MCC has induced us to a review of the literature in order to optimize the diagnostic and therapeutic approach to this tumor, and to emphasize management problems secondary to a cultural limitations that considers in our country MCC like a cancer of little
interest with a negative influence in terms of cost and survival.

2. Materials and Methods

At the Rare Hormonal Tumors Group, Department of General Surgery of Cremona Hospital, in the last 21 years we have observed 48 patients suffering from MCC in different stages of disease: stage I 28.2%, stage II 8.6%, stage III 26%, and stage IV 37% of cases. Most of the observed patients came from other institutions as a request for second opinion (at least 2/3), and for this reason the analysis of data cannot be homogeneous (Table 1). In order to stage the disease we have preferred to use the previous staging system from American Joint Committee on Cancer (AJCC) 2005 because more simple to use, and because the greatest part of the oldest literature refers to this.

There were 26 male (54.1%) and 22 female (45.8%) patients with slight male predominance. In our series MCC affects most frequently elderly patients with a mean age of 70.1 for male, and 71.2 for female (male plus female equal to 70.6, range from 52 to 95 years). MCC has been observed as a nodule of the skin in most of the cases. The extremities (40% of cases) were the most common site of incidence: follow unknown primary site (31%), head and neck (19%), buttock (8%), and trunk (1%). Half of cases had lesions with diameter <2 cm, and the other diameter equal to 2 cm or more, with a mean of 2.42 cm, and range from 0.5 to 8 cm. About proliferation cell index (ki67, MIB1 clone), we have separated the series in three different groups (ki67 10–30%, ki67 30–50%, and ki67 > 50%) in which percentage were 13.6% for the group 1, 22.7% for group 2, and 63.6% for group 3 (range from 22% to 90%). The group with the most elevated cell proliferation is prevailing, and this confirms that MCC is a particularly aggressive tumor.

In our series we have observed 3 patients with associated rheumatoid arthritis, 3 with hepatitis virus C related, 1 transplanted, 1 with Kaposi sarcoma, and 4 patients with a personal history of tumor (1 non-Hodgkin lymphoma and transplanted, 1 with Kaposi sarcoma, and 4 patients with a rheumatoid arthritis, 3 with hepatitis virus C related, 1 from anaplastic carcinoma, carcinoid tumors, retinoblastoma, sarcoma of Ewing, and neuroblastoma [15]. A high incidence of the tumor (over 600 cases) was reported in transplanted patients with a mean of 53 years (range 33–78). MCC was observed after 5–286 months from transplant (average 91.5) with characteristics of greater aggressiveness probably secondary to the immunosuppression of the patient [30–32]. The immunosuppressive situation could be the cause of metastatic MCC also in an HIV patient [33]. In our series 3 cases reported of rheumatoid arthritis associated with MCC could be secondary to immunosuppression. Since rheumatoid arthritis is considered an autoimmune disease, it is possible a predisposition to MCC among elderly patients with immune defenses reduced because of the prolonged use of steroid molecules [34].

3. Results and Discussion

The true incidence of MCC is unknown [18–20]. This tumor most frequently affects elderly patients over the age of sixty (range 7–95) [21], in 78.6% of cases [22], with a preference for women (M:F = 1 : 3) [22, 23]; MCC is most common in Caucasian populations, but occasionally is also present among blacks and Polynesians [15]. The most common site of the tumor is the skin of the head and neck (50%); in 40% of cases extremities are affected, and in 10% trunk and mucosa. Cases have also been reported of multiple sites of the disease [15, 23].

The markers normally expressed by this tumour are neuron-specific enolase (NSE) [24], chromogranins [25], and synaptophysin [26]. Vimentin and desmin are usually negative [27, 28]. Cytoplasmic granules can be rich of vasoactive intestinal polypeptide (VIP), and of met-encephalin.

The neoplasm is typically presented as an isolated, raised or flat lesion, red-purplish in colour, with a shiny surface occasionally associated with nearby telangiectasias. The epidermis may be intact or ulcerated. The tumor can occasionally be pediculate [12, 29]. The size of the neoplasm can vary greatly, up to 15 cm in diameter, with an average of 3 cm at presentation [23].

In early stage MCC doesn’t present specific characters, so that the differential diagnosis can result difficult: in fact MCC can be confused with the baso or spinocellular carcinoma, the pyogenic granuloma, the cheroatocantoma, the melanoma, the cutaneous linfoma, cutaneous metastasis from anaplastic carcinoma, carcinoid tumors, retinoblastoma, sarcoma of Ewing, and neuroblastoma [15]. A high incidence of the tumor (over 600 cases) was reported in transplanted patients with a mean of 53 years (range 33–78). MCC was observed after 5–286 months from transplant (average 91.5) with characteristics of greater aggressiveness probably secondary to the immunosuppression of the patient [30–32]. The immunosuppressive situation could be the cause of metastatic MCC also in an HIV patient [33]. In our series 3 cases reported of rheumatoid arthritis associated with MCC could be secondary to immunosuppression. Since rheumatoid arthritis is considered an autoimmune disease, it is possible a predisposition to MCC among elderly patients with immune defenses reduced because of the prolonged use of steroid molecules [34].

The staging of MCC considers a whole-body CT spiral scan because of the frequent high-proliferation index and poor differentiation of the tumor, with the aim of identifying metastatic involvement of soft tissues, sometimes associated with lytic bone lesions [35]. Positron Emission Tomography (18F-FDG-PET-CT) is an highly useful whole-body-staging method compared to conventional imaging methods, also when used as a single procedure [36, 37]. OctreoScan, using a labelled analogue of somatostatin (111In-Pentetreotide), is still considered an highly sensitive method also when compared with other conventional imaging techniques [38]. Laboratory diagnosis considers the plasmatic dosage of chromogranin A and NSE, more specific in posttreatment followup rather than during the stage of the tumor.
| Sex | Age | Site | Type          | Size (cm) | Stage | Ki67% (MIB1) | ChrA staining | NSE staining (ng/mL) | ChrA (ng/mL) | NSE (ng/mL) | Therapy          | Survival (months) | Other                  |
|-----|-----|------|---------------|-----------|-------|--------------|--------------|---------------------|--------------|-------------|------------------|-------------------|----------------------|
| F   | 83  | EXTR | NOD/ULC      | 3         | III   | —            | NEG          | POS                 | —            | —           | SURG + SMS        | 36                | RA                   |
| M   | 52  | EXTR | NOD          | —         | —     | —            | —            | —                   | —            | —           | SURG + RT         | 2                 |                      |
| F   | 76  | BUTTOCK | NOD      | 3         | II    | —            | NEG          | NEG                 | —            | —           | SURG              | —                 |                      |
| F   | 75  | EXTR | NOD          | 1         | I     | 30           | POS          | POS                 | —            | —           | SURG + RT         | 29                | RA                   |
| M   | 70  | NS   | —            | 3         | III   | >50          | NEG          | POS                 | —            | —           | SURG + SMS        | 8                 | HCV+                 |
| F   | 81  | NS   | —            | 1.5       | III   | —            | —            | —                   | —            | —           | SURG + RT + SMS   | 26                |                      |
| F   | 83  | HEAD | NOD          | 1.2       | I     | —            | NEG          | POS                 | 177          | 5.4         | SURG + RT         | 24                |                      |
| M   | 55  | BUTTOCK | NOD      | 3.5       | IV    | —            | —            | —                   | 52.2         | 39.8        | SURG + CHT        | 25                |                      |
| M   | 80  | TRUNK | NOD         | 2.2       | II    | >70          | POS          | POS                 | 43.2         | 5.5         | SURG + SMS        | 24                |                      |
| F   | 74  | HEAD | NOD/CYS     | —         | I     | —            | —            | —                   | —            | 6.3          | SURG + RT + SMS + α IFN | 15                |                      |
| M   | 70  | EXTR | NOD          | 0.8       | I     | —            | —            | —                   | —            | —           | SURG              | —                 | HCV+                 |
| F   | 72  | HEAD | NOD          | 1         | I     | 80           | —            | —                   | —            | —           | SURG              | —                 | Ca breast, Ca lung |
| F   | 63  | NS   | —            | 5         | III   | —            | —            | POS                 | 51           | 31.3        | SURG              | 25                | HCV+ Ca uterus       |
| M   | 74  | EXTR | NOD          | 1.5       | I     | —            | POS          | —                   | 136          | 5.4         | SURG              | 3                 |                      |
| M   | 70  | NS   | —            | 4         | IV    | —            | —            | —                   | —            | —           | SURG + CHT        | 12                |                      |
| M   | 85  | EXTR | NOD          | 8         | III   | 25           | POS          | —                   | 870          | 43          | SURG + SMS        | 37                | Kaposi sarcoma       |
| F   | 61  | EXTR | NOD          | 4.3       | II    | 80           | POS          | —                   | —            | —           | SURG              | —                 |                      |
| M   | 76  | HEAD | NOD          | 1.5       | III   | —            | POS          | POS                 | 185          | 8.3         | SURG              | —                 | Ca rectus            |
| F   | 84  | EXTR | NOD          | 2.0       | IV    | —            | POS          | —                   | —            | —           | SURG + CHT        | 48                |                      |
| F   | 79  | EXTR | NOD          | 1.5       | I     | —            | —            | —                   | —            | —           | SURG + RT         | —                 |                      |
| M   | 76  | EXTR | NOD          | —         | IV    | —            | —            | —                   | —            | —           | SURG + CHT        | 12                |                      |
| F   | 72  | NS   | —            | 4.5       | IV    | 80           | POS          | —                   | 70           | 81.2        | SURG + CHT + SMS  | 58                |                      |
| M   | 55  | EXTR | NOD          | 1         | III   | —            | NEG          | —                   | —            | —           | SURG              | —                 |                      |
| F   | 80  | EXTR | NOD/ULC     | 1.7       | I     | 80           | POS          | —                   | —            | —           | SURG              | —                 |                      |
| M   | 67  | HEAD | NOD          | 0.5       | I     | —            | —            | —                   | —            | —           | SURG              | —                 |                      |
| M   | 70  | NS   | —            | —         | IV    | 70           | —            | —                   | 46           | 13          | SURG + CHT        | 16                |                      |
| M   | 70  | EXTR | NOD          | 2         | IV    | 40           | —            | —                   | 99.3         | 17.8        | SURG + RT + CHT + SMS | 27                |                      |
| F   | 61  | NS   | —            | 6         | IV    | 50           | —            | —                   | 50           | 21.3        | SURG + CHT        | —                 |                      |
| M   | 63  | BUTTOCK | NOD      | 5         | IV    | 50           | POS          | —                   | —            | —           | SURG              | 15                | LNH                  |
| M   | 95  | HEAD | NOD          | 1.2       | I     | 70           | POS          | —                   | —            | —           | SURG              | —                 |                      |
| M   | 80  | HEAD | NOD          | 0.5       | IV    | —            | —            | —                   | 46           | 8.9         | SURG + RT + CHT + SMS + RMT | 17                |                      |
| M   | 74  | NS   | —            | —         | IV    | —            | NEG          | —                   | —            | —           | SURG + RT + CHT + SMS | 23                |                      |
| F   | 69  | EXTR | NOD          | —         | IV    | —            | —            | —                   | —            | —           | SURG              | —                 |                      |
| M   | 64  | NS   | —            | 3         | II    | 60           | POS          | —                   | 156          | 8.0         | SURG              | —                 |                      |
| F   | 60  | HEAD | NOD          | 0.7       | I     | 90           | POS          | —                   | —            | —           | SURG              | —                 |                      |
| M   | 89  | BUTTOCK | NOD      | —         | IV    | 80           | POS          | —                   | 760          | 86.2        | SURG + RT + CHT  | 13                |                      |
Table 1: Continued.

| Sex | Age | Site Type | Size (cm) | Stage | Ki67% (MIB1) | ChrA staining | NSE staining (ng/mL) | ChrA (ng/mL) | NSE (ng/mL) | Therapy | Survival (months) | Other |
|-----|-----|-----------|----------|-------|-------------|---------------|---------------------|--------------|-------------|---------|-----------------|-------|
| F   | 65  | EXTR NOD | —        | —     | —           | —             | —                   | —            | —           | SURG    | —               |       |
| M   | 59  | EXTR NOD |          | 1     | III         | POS           | —                   | —            | —           | SURG    | 6               | RA    |
| M   | 64  | HEAD NOD | 1.1      | III   | 60          | POS           | —                   | —            | —           | SURG    | —               |       |
| F   | 59  | EXTR NOD | 0.6      | I     | 22          | POS           | —                   | —            | —           | SURG    | 17              |       |
| M   | 75  | NS        | 4        | IV    | 35          | POS           | —                   | —            | —           | SURG    | 6 HCV+          |       |
| F   | 59  | NS        | 1        | 1     | 40          | POS           | —                   | —            | —           | SURG    | 14              |       |
| F   | 78  | EXTR NOD | 2.5      | III   | —           | —             | —                   | —            | —           | SURG    | —               |       |
| F   | 60  | NS        | —        | IV    | —           | —             | —                   | —            | —           | SURG    | — Paraneoplastic polineuritis Transpl |       |
| M   | 69  | EXTR NOD | 2        | III   | 35          | POS           | POS                 | 116          | 10          | SURG + RT | 5                |       |
| F   | 74  | NS        | —        | 6     | IV          | POS           | —                   | 700          | 102         | SURG + CHT + SMS | 52    |
| M   | 58  | NS        | 2.5      | III   | 80          | POS           | POS                 | 46.5         | 5.3         | SURG + RT | —                |       |
| M   | 63  | NS        | 1.2      | IV    | 80          | POS           | —                   | 1500         | 17.20       | SURG + CHT + SMS | 22    |

AR: rheumatoid arthritis, ChrA: chromogranin A, 19–98 ng/mL, CHT: chemotherapy, EXTR: extremities, F: female, αIFN: alpha interferon, M: male, NS: no skin (unknown primary site), NSE: neuron-specific enolase, <12 ng/mL, RM: receptor radionuclide therapy, RT: radiotherapy, SMS: somatostatin analogues, SURG: Surgery, TRANS: transplanted.

Table 2: Merkel cell carcinoma staging system, 2005 [40].

| Stage | TNM | OS 2y | OS 5y |
|-------|-----|-------|-------|
| Stage I | Primary < 2 cm (T1) | 67% | 81% |
| Stage II | Primary 2 cm or more (T2) | 59% | 67% |
| Stage III | Nodal disease (N1) | 49% | 52% |
| Stage IV | Systemic metastases (M1) | 23% | 11% |

Patients affected by MCC can be classified using the last classification AJCC 2010, more online with other skin malignancies, although more complicated to use [39]. Because of this, the literature often refers to the previous staging system from AJCC 2005 [40], more simple to use, but making comparison is difficult with newer studies that consider the last classification. For this reason, we preferred to refer to the classification AJCC 2005 in order to give more homogeneity to our older cases staged by this classification (Table 2).

3.1. Surgery. In stage I and II, surgical is the treatment of choice represented by the excision of the primitive lesion [15, 41–44]. In order to avoid local recurrence, an adequate resection margin at least of 2 cm is required [45, 46]. A more wide excision provides a significant reduction in local recurrence rate by increasing the margin from 1 to 3 cm [15, 47, 48]. In our series of 8 cases from other institutions, a wide excision was not considered after histological examination causing a local relapse to distance. The necessity of elective lymph nodal treatment is controversial. Tumor size >1 cm was found to be a poor prognostic factor [49], and 2 cm can be a significant cut off for poor prognosis [34, 40]. For these reasons, and also in relationship with our experience, we suggest that Sentinel Lymph Node Biopsy (SLNB) should always be considered [50]. SLNB detects MCC spread in one-third of patients understaged, and those who did not receive treatment that involved nodes [51]; this method identifies occult nodal metastases in 29% of patients with localized MCC [52]. About this method, in our series we have observed a higher sensibility using 18F-scan rather than 99Tc-scan. Finally, in absence of SLNB, adjuvant radiotherapy to the primary and nodal region should be delivered.

3.2. Radiotherapy. The greatest part of authors are in favor to consider adjuvant postoperative radiotherapy routinely. This choice is associated with a reduced risk of local recurrence [53, 54]. Radiant treatment (40–60 Gy) should follow surgical excision [55] in order to prevent the progression of disease in stage I and II with development of lymph nodal metastases in 40–73% of the cases and local relapse in 23–60% of the cases [56], with a disease free survival only up to 8 months [45]. In these cases surgical debulking can be associated with more sustained radiant regimes with survival in approximately 60% of cases [15], and a disease free survival from 3 to 30 months (average 8 months) [57]. The largest series from SEER data shows median survival for adjuvant radiotherapy up to 63 months compared with median survival without radiant therapy up to 45 months. Radiotherapy is associated with an increased survival particularly for primary lesions greater than 2 cm [58]. In another series from Canada and Australia, combined surgery and radiotherapy improves both loco-regional control and disease-free survival [49]. On the contrary, adjuvant chemotherapy does not reduce the rate of local relaps or improve survival [59]. We have observed 10 cases from other institutions with local relapse due to the absence of prior radiant therapy that were in need of surgical debulking.
3.3. Radiotherapy Alone. Radiotherapy as primary treatment is essential in cases of locally advanced tumors or invasion of critical structures with difficult resectability. It was reported, a study on 3 cases with complete response after primary radiotherapy, and the absence of local relapses for up to 3 years [60]. In a retrospective study there were no statistical differences and disease-free survival between two different groups (radiotherapy alone versus conventional therapy) [61]. In a series of 50 patients, lymph node radiation alone in metastatic nodes has resulted in a great percentage of local control compared with lymphadenectomy alone on both microscopic and palpable nodes, and no differences for overall survival [62].

3.4. Chemotherapy. Advanced disease is characteristic of stage IV. Chemotherapy treatment considers a wide range of molecules used both in monotherapy and in combination, as etoposide, carboplatin, doxorubicin, dacarbazine, vincristine, cyclophosphamide, and methotrexate. Chemotherapy shows a surprising objective response at beginning of treatment (61%) with a progressive drop during a second (45%), and a third line of therapy (20%) [63] with a very short duration, from 3.5 to 12 months [64, 65]. In the TROG study, synchronous carboplatin/etoposide plus radiation have been achieved high levels of locoregional control and survival [66], in contrast with a retrospective study from the same group [67].

3.5. Other Methods. Local infiltration of α-2b IFN [68], tumor necrosis factor (TNF) [69], hyperthermia in association with low doses of radiotherapy [70], or radiotherapy with TNF-α, IFN γ, and melphalan [71], have showed occasional remissions with relatively long, but anecdotal, disease-free survival. Among the immunomodulatory molecules, imiquimod combined with radiotherapy has suggested the possible use effective with a complete response up to 7 months in a case reported of MCC of the head [72]. About somatostatin analogues treatment, there is a few number of reports in literature. In one case of metastatic MCC from our series, the treatment with octreotide showed an immediate objective response with a moderate dose (1 mg/day subcutis), in absence of significant side effects and survival over 10 months from the start of therapy [73]; moreover, in 2 cases observed, OctreoScan was been able to determine a partial regression of local relapse, even before starting treatment with somatostatin analogues. In another case reported of local advanced and recurrent MCC of the head, treatment with lanreotide at the dose of 15 mg intramuscular every two weeks showed a favorable course after 17 months from the start of therapy [74]. In other case of metastatic MCC reported treated with octreotide has been observed a favorable course up to 3 years with a good quality of life [75]. Somatostatin analogues can play a role in the therapy of metastatic MCC, in alternative to chemotherapy, limited to selected cases with mild aggressive disease, and with significant density in vivo for somatostatin receptors. In our series, somatostatin analogues represent a wide slice in the treatment of MCC (29% of cases) in different modalities of association. Receptor radionuclide therapy is reported only in one case after relapse from MCC in a elderly patient, with a good response [76]. In our series we have treated only one elderly patient suffering from MCC with 177Lu-DOTATATE (1.5 GBq), already submitted to other therapies, and probably in a too advanced stage to consent a response.

4. Conclusions

MCC is a highly aggressive cancer of the skin with 30% of mortality. The incidence in USA has increased threefold and became the second common cause of nonmelanoma skin cancer death [77]. The most common features were used to create a simple acronym: AEIOU (asymptomatic/lack of...
tenderness, expanding rapidly <3 months, immunosuppression, older than 50, and location on an ultraviolet-exposed site). These criteria can allow as a clue in the diagnosis of MCC, with three or more criteria in 89% of cases in a series of 195 patients [78]. In relation to the current knowledge, the correct management for MCC is the aggressive and radical excision of the lesion in its early stage in order to reduce the rate of relapse, and to improve survival. Surgery is the mainstay of treatment for MCC when feasible. Outcome depends mainly on the early and wide excision [79], and on sequential radiotherapy, in order to avoid local relapse and/or progressive disease, as also confirmed from our personal observations. In this way, the role of SLNB is in our opinion fundamental also in stage I, given that size of lesion may not match the malignancy of the tumor. About chemotherapy, its role should be revisited that size of lesion may not match the malignancy of the tumor. About chemotherapy, its role should be reconsidered in a significant part of cases from other institutions we were not able to get further information about the progress of disease. About MCC from unknown primary site (31% in

several independent groups [83]. The integration of this virus before the tumor development supports a role for polyomavirus in tumorigenesis process [84]. In this way, prophylaxis with vaccination against Merkel cell polyomavirus should be possible in high-risk patients, in the future.

In our opinion, our series highlights a number of interesting aspects. The first concerns the number of patients observed. The great number of patients in our case series can suggest the consideration that the MCC, although considered a low-tumor incidence, it is not so quite rare. The second aspect concerns the cultural approach to the problem. Looking at the cases with advanced disease from other institutions, it is evident that the large number of patients to whom it was not proposed or wide surgical excision, or radiotherapy, or both: thus clearly demonstrates the lack of expertise in the management of MCC, and because of the high aggressiveness of MCC, it is subsequently assumed the highest rate of local relapses or metastatic disease. The third aspect relates to the timing in the management of MCC. We have observed several cases where the choice to remove the primary lesion was made after so many months from the onset of disease, and several cases with long latency between histological diagnosis and subsequent treatment decisions. In one case there was not even the histological examination of the primary lesion and in another even that of relapse. These observations are once again due to the lack of experience for MCC, but also towards a management too superficial in regard to a tumor too underestimated. The fourth point concerns the treatment of metastatic disease. Chemotherapy should be considered at present the standard treatment in advanced disease: but in our series we can observe the frequent use of different molecules (particularly somatostatin analogues) for patients from other institutions, which cannot be considered appropriate to control metastatic disease and even related symptoms. The fifth point relates to the lack of diagnostic and therapeutic protocols, a problem affecting almost the entire management of rare tumors. This question also involves the management of MCC and is highlighted by the large number of second opinion requests. The lack of protocols is partly covered by some guidelines (in Italy by the guidelines from ROL, Rete Oncologica Lombarda) in many cases not known and in many other cases disregarded. The sixth and final point concerns the last classification of MCC, which in our opinion is too complex with the result of a difficult staging, and the consequence of a therapeutic approach to disease not always easy, another reason that makes us still choose the previous staging system from AJCC 2005.

All these reasons lead clearly to the impossibility having concrete data of survival. In our series the survival rate was calculated considering the distance in time between first diagnosis and our last control of patient. Since the majority of patients we have considered as second opinion in different stages of disease, and the greatest part of these in advanced disease (stage IV) or in presence of local relapse, it is not possible to report the correct data of survival. Furthermore, in a significant part of cases from other institutions we were not able to get further information about the progress of disease. About MCC from unknown primary site (31% in

![Figure 2: Algorithm for advanced or locally relapsed MCC.](image-url)
our series), survival appears very low (average 24 months) but conditioned by a very significant late diagnosis up to 18 months, and few treatment options [85]. Finally, we believe that the comprehensive evaluation of the patient integrated with imaging and laboratory parameters can allow to find the right direction for a balanced choice of therapy and not always immediately easy. It will nevertheless require a cultural change in the approach of MCC as in case of other rare tumors (Figures 1 and 2) [50, 86].

References

[1] C. Toker, "Trabecular carcinoma of the skin," Archives of Dermatology, vol. 105, no. 1, pp. 107–110, 1972.
[2] C. K. Tang and C. Toker, "Trabecular carcinoma of the skin: an ultrastructural study," Cancer, vol. 42, no. 5, pp. 2311–2321, 1978.
[3] C. Toker, "Trabecular carcinoma of the skin: a question of title," American Journal of Dermatopathology, vol. 4, no. 6, pp. 497–500, 1982.
[4] J. B. Stern, "‘Murky cell’ carcinoma (formerly trabecular carcinoma). A reply in which yet another name is revealed at the very end," American Journal of Dermatopathology, vol. 4, no. 6, pp. 517–519, 1982.
[5] A. M. Rywlin, "Malignant Merkel-cell tumor is a more accurate description than trabecular carcinoma," American Journal of Dermatopathology, vol. 4, no. 6, pp. 513–515, 1982.
[6] G. S. Sidhu, "What’s in a name? Should it be Merkel cell neoplasm or trabecular carcinoma?" American Journal of Dermatopathology, vol. 4, no. 6, pp. 509–511, 1982.
[7] C. Urmacher, "Trabecular carcinoma is an accurate designation," American Journal of Dermatopathology, vol. 4, no. 6, p. 507, 1982.
[8] J. Rosai, "On the nature and nomenclature of a primary small carcinoma of the skin exhibiting endocrine (?Merkel cell) differentiation," American Journal of Dermatopathology, vol. 4, no. 6, pp. 501–505, 1982.
[9] R. K. Sibley, J. Rosai, and E. Foucar, "Neuroendocrine (Merkel cell) carcinoma of the skin. A histologic and ultrastructural study of two cases," American Journal of Surgical Pathology, vol. 4, no. 3, pp. 211–221, 1980.
[10] E. Silva and B. Mackay, "Neuroendocrine (Merkel cell) carcinomas of the skin: an ultrastructural study of nine cases," Ultrastructural Pathology, vol. 2, no. 1, pp. 1–9, 1981.
[11] C. De Wolf-Peeters, K. Marien, J. Mebis, and V. Desmet, "A cutaneous APUDoma or Merkel cell tumor? A morphologically recognizable tumor with a biological and histological malignant aspect in contrast with its clinical behavior," Cancer, vol. 46, no. 8, pp. 1810–1816, 1980.
[12] B. Frigerio, C. Capella, and V. Eusebi, "Merkel cell carcinoma of the skin: the structure and origin of normal Merkel cells," Histopathology, vol. 7, no. 2, pp. 229–249, 1983.
[13] A. G. E. Pearse, "The neuroendocrine (APUD) cells of the skin," American Journal of Dermatopathology, vol. 2, no. 2, pp. 121–123, 1980.
[14] K. Hashimoto, "The ultrastructure of the skin of human embryos. X. Merkel tactile cells in the finger and nail," Journal of Anatomy, vol. 111, no. 1, pp. 99–120, 1972.
[15] D. Ratner, B. R. Nelson, M. D. Brown, and T. M. Johnson, "Merkel cell carcinoma," Journal of the American Academy of Dermatology, vol. 29, no. 2, pp. 143–160, 1993.
[16] K. B. English, "Morphogenesis of haarscheiben in rats," Journal of Investigative Dermatology, vol. 69, no. 1, pp. 58–67, 1977.
[17] F. Cirillo, "Neuroendocrine tumors and their association with rare tumors: observation of 4 cases," European Review for Medical and Pharmacological Sciences, vol. 14, no. 7, pp. 577–588, 2010.
[18] A. Di Cataldo, G. Li Destri, R. A. Ciraldo RA et al., "Il carcinoma neuroendocrino a cellule di Merkel della cute," Chirurgia, vol. 5, pp. 527–530, 1982.
[19] T. Kivela and A. Tarkkanen, "The Merkel cell and associated neoplasms in the eyelids and periocular region," Survey of Ophthalmology, vol. 35, no. 3, pp. 171–187, 1990.
[20] L. L. Anderson, T. J. Phipps, and M. L. McCollough, "Neuroendocrine carcinoma of the skin (Merkel cell carcinoma) in a black," Journal of Dermatologic Surgery and Oncology, vol. 18, no. 5, pp. 375–380, 1992.
[21] T. Y. Chuang, W. P. D. Su, and S. A. Muller, "Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population," Journal of the American Academy of Dermatology, vol. 23, no. 2 I, pp. 254–256, 1990.
[22] S. Zanardi, L. Canobbio, R. Torrisi, D. Cannata, and E. Boccardo, "Le neoplasie neuroendocrine. Aspetti nosografici, anatomo-patologici e clinici (1)," Argomenti Di Oncologia, vol. 15, pp. 23–36, 1994.
[23] U. Meyer-Pannwitt, K. Kummerfeldt, P. Boubaris, and J. Caselitz, "Merkel cell carcinoma," Langenbecks Archiv fur Chirurgie, vol. 382, no. 6, pp. 349–358, 1997.
[24] J. Gu, J. M. Polak, and S. Van Noorden, "Immunostaining of neuron-specific enolase as a diagnostic tool for Merkel cell tumors," Cancer, vol. 52, no. 6, pp. 1039–1043, 1983.
[25] B. S. Wilson and R. V. Lloyd, "Detection of chromogranin in neuroendocrine cells with a monoclonal antibody," American Journal of Pathology, vol. 115, no. 3, pp. 458–468, 1984.
[26] J. P. Ortonne, J. P. Petchot-Bacque, P. Verrando, A. Pisani, G. Pautrat, and F. Bernerd, "Normal Merkel cells express a synaptophysin-like immunoreactivity," Dermatologica, vol. 177, no. 1, pp. 1–10, 1988.
[27] V. E. Gould, R. Moll, and I. Moll, "Neuroendocrine (Merkel) cells of the skin: hyperplasias, dysplasias, and neoplasms," Laboratory Investigation, vol. 52, no. 4, pp. 334–353, 1985.
[28] W. Hartschuh, E. Weihe, N. Yanaihara, and M. Reinecke, "Immunohistochemical localization of vasoactive intestinal polypeptide (VIP) in Merkel cells of various mammals: evidence for a neuromodulator function of the Merkel cell," Journal of Investigative Dermatology, vol. 81, no. 4, pp. 361–364, 1983.
[29] T. C. Chao, J. M. Park, H. Rhee, and J. A. Greager, "Merkel cell tumor of the back detected during pregnancy," Plastic and Reconstructive Surgery, vol. 86, no. 2, pp. 347–351, 1990.
[30] M. J. Veness, "Aggressive skin cancers in a cardiac transplant recipient," Australasian Radiology, vol. 41, no. 4, pp. 363–366, 1997.
[31] R. H. Williams, M. B. Morgan, I. M. Mathieson, and H. Rabb, "Merkel cell carcinoma in a renal transplant patient: increased incidence?" Transplantation, vol. 65, no. 10, pp. 1396–1397, 1998.
[32] I. Penn and M. R. First, "Merkel’s cell carcinoma in organ recipients: report of 41 cases," Transplantation, vol. 68, no. 11, pp. 1717–1721, 1999.
[33] P. Samarendra, L. Berkowitz, S. Kumari, and R. Alexis, "Primary nodal neuroendocrine (Merkel cell) tumor in a patient with HIV infection," Southern Medical Journal, vol. 93, no. 9, pp. 920–922, 2000.
[34] F. Cirillo, M. Buononato, G. Lima, I. Cafaro, and P. Alquati, "Clinical experience on eight cases of Merkel cell carcinoma," Tumori, vol. 89, no. 2, pp. 146–151, 2003.
[35] F. Eftekhar, S. Wallace, E. G. Silva, and R. Lenzi, "Merkel cell carcinoma of the skin: imaging and clinical features in 93 cases," British Journal of Radiology, vol. 69, no. 819, pp. 226–233, 1996.

[36] G. Maury, D. Dereure, A. Du-Thanh, D. Mariano-Goulart, and B. Guillot, "Interest of (18)F-FDG PET-CT scanning for staging and management of merkel cell carcinoma: a retrospective study of 15 patients," Journal of the European Academy of Dermatology and Venereology, vol. 25, no. 12, pp. 1420–1427, 2011.

[37] P. Peloschek, C. Novotny, C. Mueller-Mang et al., "Diagnostic imaging in Merkel cell carcinoma: lessons to learn from 16 cases with correlation of sonography, CT, MRI and PET," European Journal of Radiology, vol. 73, no. 2, pp. 317–323, 2010.

[38] S. W. J. Lamberts, E. P. Krenning, and J. C. Reubi, "The role of somatostatin and its analogs in the diagnosis and treatment of tumors," Endocrine Reviews, vol. 12, no. 4, pp. 450–482, 1991.

[39] American Joint Committee on Cancer Staging Handbook, Merkel Cell Carcinoma, Springer, New York, NY, USA, 2010.

[40] P. J. Allen, W. B. Bowne, D. P. Jaques, M. F. Brennan, K. Busam, and D. G. Coit, "Merkel cell carcinoma: prognosis and treatment of patients from a single institution," Journal of Clinical Oncology, vol. 23, no. 10, pp. 2300–2309, 2005.

[41] J. H. Raaf, C. Urmacher, and W. K. Knapper, "Trabecular (Merkel) cell carcinoma of the skin. Treatment of primary, recurrent, and metastatic disease," Cancer, vol. 57, no. 1, pp. 178–182, 1986.

[42] J. Tennwall, A. Biorklund, L. Johansson, and M. Akerman, "Merkel cell carcinoma: management of primary, recurrent and metastatic disease. A clinicopathological study of 17 patients," European Journal of Surgical Oncology, vol. 15, no. 1, pp. 1–9, 1989.

[43] S. Pilotti, F. Rilke, C. Bartoli, and A. Grisotti, "Clinicopathologic correlations of cutaneous neuroendocrine Merkel cell carcinoma," Journal of Clinical Oncology, vol. 6, no. 12, pp. 1863–1873, 1988.

[44] E. G. Silva, B. Mackay, H. Goepfert, M. A. Burgess, and R. S. Fields, "Endocrine carcinoma of the skin (Merkel cell carcinoma)," Pathology Annual, vol. 19, pp. 1–30, 1984.

[45] M. J. Ott, K. K. Tanabe, M. A. Gadd et al., "Multimodality management of Merkel cell carcinoma," Archives of Surgery, vol. 134, no. 4, pp. 388–393, 1999.

[46] H. Goepfert, D. Remmier, E. Silva, and B. Wheeler, "Merkel cell carcinoma (endocrine carcinoma of the skin) of the head and neck," Archives of Otolaryngology, vol. 110, no. 11, pp. 707–712, 1984.

[47] A. Yiengpruksawan, D. G. Coit, H. T. Thaler, C. Urmacher, and W. K. Knapper, "Merkel cell carcinoma: prognosis and management," Archives of Surgery, vol. 126, no. 12, pp. 1514–1519, 1991.

[48] C. L. Hitchcock, K. I. Bland, R. G. Laney, D. Franzini, B. Harris, and E. M. Copeland III, "Neuroendocrine (Merkel cell) carcinoma of the skin. Its natural history, diagnosis, and treatment," Annals of Surgery, vol. 207, no. 2, pp. 201–207, 1988.

[49] J. R. Clark, M. J. Veness, R. Gilbert, C. J. O’Brien, and P. J. Gullane, "Merkel cell carcinoma of the head and neck: is adjuvant radiotherapy necessary?" Head and Neck, vol. 29, no. 3, pp. 249–257, 2007.

[50] A. Assouline, P. Tai, K. Joseph, J. L. Dong Lian, C. Krzisch, and E. Yu, "Merkel cell carcinoma of skin—current controversies and recommendations," Rare Tumors, vol. 3, article e23, pp. 71–75, 2011.

[51] S. G. Gupta, L. C. Wang, P. F. Peñas, M. Gellenthin, S. J. Lee, and P. Nghiem, "Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: the Dana-Farber experience and meta-analysis of the literature," Archives of Dermatology, vol. 142, no. 6, pp. 685–690, 2006.

[52] R. C. Fields, K. J. Busam, J. F. Chou et al., "Recurrence and survival in patients undergoing sentinel lymph node biopsy for merkel cell carcinoma: analysis of 153 patients from a single institution," Annals of Surgical Oncology, vol. 18, no. 9, pp. 2529–2537, 2011.

[53] W. H. Morrison, L. J. Peters, E. G. Silva, C. D. Wendt, K. Kian Ang, and H. Goepfert, "The essential role of radiation therapy in securing locoregional control of Merkel cell carcinoma," International Journal of Radiation Oncology Biology Physics, vol. 19, no. 3, pp. 583–591, 1990.

[54] H. Medina-Franco, M. M. Urist, J. Fiveash, M. J. Heslin, K. I. Bland, and S. W. Beenken, "Multimodality treatment of merkel cell carcinoma: case series and literature review of 1024 cases," Annals of Surgical Oncology, vol. 8, no. 3, pp. 204–208, 2001.

[55] M. E. Marks, R. Y. Kim, and M. M. Salter, "Radiotherapy as an adjuvant in management of Merkel cell carcinoma," Cancer, vol. 65, no. 1, pp. 60–64, 1990.

[56] P. Savage, D. Constenla, C. Fisher, J. M. Thomas, and M. E. Gore, "The natural history and management of merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital," Clinical Oncology, vol. 9, no. 3, pp. 164–167, 1997.

[57] R. M. Nathu, W. M. Mendenhall, and J. T. Parsons, "Merkel cell carcinoma of the skin," Radiation Oncology Investigations, vol. 6, pp. 233–239, 1998.

[58] P. Mojica, D. Smith, and J. D. I. Ellenhorn, "Adjuvant radiation therapy is associated with improved survival in merkel cell carcinoma of the skin," Journal of Clinical Oncology, vol. 25, no. 9, pp. 1043–1047, 2007.

[59] E. R. Kokoska, M. S. Kokoska, B. T. Collins, D. R. Stapleton, and T. P. Wade, "Early aggressive treatment for merkel cell carcinoma improves outcome," American Journal of Surgery, vol. 174, no. 6, pp. 688–693, 1997.

[60] M. A. Ashby, D. H. Jones, A. D. Tasker, and A. J. Blackshaw, "Primary cutaneous neuroendocrine (Merkel cell or trabecular carcinoma) tumour of the skin: a radioresponsive tumour," Clinical Radiology, vol. 40, no. 1, pp. 85–87, 1989.

[61] E. Pape, N. Rezvov, N. Penel et al., "Radiotherapy alone for Merkel cell carcinoma: a comparative and retrospective study of 25 patients," Journal of the American Academy of Dermatology, vol. 65, no. 5, pp. 983–990, 2011.

[62] L. C. Fang, B. Lemos, J. Douglas, J. Iyer, and P. Nghiem, "Radiation monotherapy as regional treatment for lymph node-positive merkel cell carcinoma," Cancer, vol. 116, no. 7, pp. 1783–1790, 2010.

[63] E. Voog, P. Biron, J. P. Martin, and J. Y. Blay, "Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma," Cancer, vol. 85, pp. 2589–2595, 1999.

[64] D. Sharma, G. Flora, and S. M. Grunberg, "Chemotherapy of metastatic Merkel cell carcinoma: case report and review of the literature," American Journal of Clinical Oncology, vol. 14, no. 2, pp. 166–169, 1991.

[65] J. Redmond III, J. Perry, P. Sowray, S. J. Vukelja, and N. Dawson, "Chemotherapy of disseminated merkel-cell carcinoma," American Journal of Clinical Oncology, vol. 14, no. 4, pp. 305–307, 1991.
[66] M. Poulsen, D. Rischin, E. Walpole et al., “High-risk Merkel cell carcinoma of the skin treated with synchronous carboplatin/etoposide and radiation: a Trans-Tasman Radiation Oncology Group Study-TROG 9607,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4371–4376, 2003.

[67] M. G. Poulsen, D. Rischin, I. Porter et al., “Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin?” International Journal of Radiation Oncology Biology Physics, vol. 64, no. 1, pp. 114–119, 2006.

[68] J. M. Durand, C. Weiller, M. A. Richard, I. Portal, and M. M. G. Poulsen, D. Rischin, E. Walpole et al., “High-risk Merkel cell carcinoma of the skin?” Journal of Oncology, vol. 9, pp. 33–40, 2003.

[69] Y. Hata, K. Matsuka, O. Ito et al., “Two cases of Merkel cell carcinoma cured by intratumor injection of natural human tumor necrosis factor,” Plastic and Reconstructive Surgery, vol. 99, no. 2, pp. 547–553, 1997.

[70] S. J. Knox and D. S. Kapp, “Hyperthermia and radiation therapy in the treatment of recurrent Merkel cell tumors,” Cancer, vol. 62, no. 8, pp. 1479–1486, 1988.

[71] A. F. T. Olieman, D. Liénard, A. M. M. Eggermont et al., “Hyperthermic isolated limb perfusion with tumor necrosis factor α, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study,” Archives of Surgery, vol. 134, no. 3, pp. 303–307, 1999.

[72] M. Balducci, B. De Bari, S. Manfrida, G. R. D’Agostino, and V. Valentini, “Treatment of Merkel cell carcinoma with radiotherapy and imiquimod (Aldara): a case report,” Tumori, vol. 96, no. 3, pp. 508–511, 2010.

[73] F. Cirillo, L. Filipponi, G. F. Lima, G. Caresana, and P. Alquati, “Tumore a cellule di Merkel: segnalazione di un caso e trattamento con octreotide,” Minerva Chirurgica, vol. 52, no. 11, pp. 1359–1365, 1997.

[74] M. Fakiha, P. Letertre, J. P. Vuillez, and J. Lebeau, “Remission of Merkel cell tumor after somatostatin analog treatment,” Journal of Cancer Research and Therapeutics, vol. 6, no. 3, pp. 382–384, 2010.

[75] M. T. Grosse Perdekamp and M. H. Zarrabi, “Treatment of metastatic Merkel cell tumor with Octreotide: report of two cases and review of the literature,” in ASCO Annual Meeting, vol. 20, abstract 235, 2001.

[76] G. Meier, C. Waldherr, R. Herrmann, H. Maecke, J. Mueller-Brand, and M. Pless, “Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma: a case report,” Oncology, vol. 66, no. 2, pp. 160–163, 2004.

[77] N. C. Hodgson, “Merkel cell carcinoma: changing incidence trends,” Journal of Surgical Oncology, vol. 89, no. 1, pp. 1–4, 2005.

[78] M. Heath, N. Jaimes, B. Lemos et al., “Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features,” Journal of the American Academy of Dermatology, vol. 58, no. 3, pp. 375–381, 2008.

[79] J. R. Howle, T. M. Hughes, V. Gebski, and M. J. Veness, “Merkel cell carcinoma: an Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients,” Journal of the American Academy of Dermatology, vol. 67, no. 1, pp. 33–40, 2012.

[80] K. Krasagakis, S. Krüger-Krasagakis, J. Eberle, A. Tsatsakis, A. D. Tosca, and E. N. Stathopoulos, “Co-expression of KIT receptor and its ligand stem cell factor in Merkel cell carcinoma,” British Journal of Dermatology, vol. 218, no. 1, pp. 37–43, 2008.

[81] L. Kondapalli, K. Soltani, and M. E. Lacouture, “The promise of molecular targeted therapies: protein kinase inhibitors in the treatment of cutaneous malignancies,” Journal of the American Academy of Dermatology, vol. 53, no. 2, pp. 291–302, 2005.